SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Beyond their metabolic effects, SGLT2 inhibitors exhibit anti-inflammatory properties, reducing both systemic and hepatic inflammation—a critical factor in preventing the progression of MASLD to more advanced stages, such as NASH and fibrosis [51, 52].